Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TK2 | O00142 | 1/20 | 0.36 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.35 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23264576 | 1.00 | TK1 (0.41) | TK1HPGDALDH1A1TK2NT5M | |
| SCHEMBL26738687 | 1.00 | TK1 (0.41) | TK1HPGDALDH1A1TK2NT5M | |
| SCHEMBL23264572 | 1.00 | TK1 (0.41) | TK1HPGDALDH1A1TK2NT5M | |
| SCHEMBL1096648 | 0.91 | TK1 (0.42) | TK1HPGDALDH1A1TK2NT5M | |
| SCHEMBL1096225 | 0.91 | TK1 (0.42) | TK1HPGDALDH1A1TK2NT5M | |
| SCHEMBL3271976 | 0.86 | TK1 (0.42) | TK1HPGD | |
| SCHEMBL4554920 | 0.86 | TK1 (0.42) | TK1HPGD | |
| SCHEMBL29485742 | 0.85 | TK1 (0.42) | TK1HPGDTK2NT5MRNASE1 | |
| SCHEMBL29485721 | 0.84 | TK1 (0.42) | TK1HPGDTK2NT5MRNASE1 | |
| SCHEMBL20394066 | 0.84 | TK1 (0.43) | TK1HPGDALDH1A1TK2NT5M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| EP-2862868-B1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO CO LTD (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-9738681-B2 | Intermediate for production of nucleoside analog and method for producing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-10 | — | — | US | disclosed |
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862868-A1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | TK1 54/4885HPGD 4234/4885ALDH1A1 2978/4885 |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | TK1 54/4885HPGD 4234/4885ALDH1A1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.